MYGN

Business Context and Reporting Period

Company: Myriad Genetics, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2003
Business Overview: Myriad is a biopharmaceutical company focused on developing therapeutic products and predictive medicine tests. Key products include BRACAnalysis (breast/ovarian cancer risk), COLARIS (colon cancer risk), and MELARIS (melanoma risk). The company is also advancing drug discovery programs, notably Flurizan (MPC-7869) for prostate cancer and Alzheimer's disease.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Total revenues decreased 12% year-over-year. While Predictive Medicine revenue grew 3% to $8.1 million, Research revenue dropped 27% to $5.6 million. The decline in research revenue is primarily due to the completion of the Hitachi collaboration in April 2003.
• Increased Expenses: Research and development (R&D) expenses rose 19% to $13.0 million, driven by clinical trials for prostate cancer and Alzheimer's disease. Selling, general, and administrative (SG&A) expenses increased 5% to $8.1 million.
• Widened Loss: The operating loss expanded from $6.1 million to $10.2 million, and the net loss increased from $5.3 million to $9.6 million.
• Improved Margins: Despite higher costs, the gross margin for predictive medicine improved to 66% from 63% in the prior year due to technology and efficiency gains.
• Cash Flow: Net cash used in operating activities improved (decreased) by $4.4 million compared to the prior year, largely due to a decrease in other receivables and changes in accounts payable.

Guidance, Outlook, and Risks

• Outlook: Management expects to incur losses for at least the next several years due to the expansion of drug discovery, clinical trials, and new product launches. The company believes existing capital resources are sufficient to fund operations for at least the next two years.
• Clinical Progress: Flurizan (MPC-7869) is in a large multi-center trial for prostate cancer and Phase I/II trials for Alzheimer's disease.
• Legal Contingency: The company is involved in an arbitration proceeding where a third party is seeking approximately $5.5 million plus interest regarding licensing royalties. Management intends to vigorously defend the claim and has not accrued a liability as the outcome is not currently estimable.
• Capital Resources: The company has a shelf registration statement allowing for the sale of up to $250 million in securities, with approximately $193 million currently available.
• Risks: Key risks include the failure of clinical trials, inability to secure regulatory approval, dependence on collaborations, and the unpredictability of the ongoing arbitration.

Investor Verification Checklist

• Arbitration Outcome: Monitor the status of the $5.5 million arbitration claim regarding licensing royalties.
• Clinical Trial Results: Verify the progress and data readouts for Flurizan (MPC-7869) in prostate cancer and Alzheimer's disease trials.
• Research Revenue Pipeline: Assess the company's ability to replace the lost revenue from the completed Hitachi collaboration with new research agreements.
• Cash Burn Rate: Track the quarterly cash burn rate against the $111 million in total liquid assets (cash and marketable securities) to confirm the two-year runway estimate.
• Stock-Based Compensation: Note that reported net loss excludes stock-based compensation; pro forma net loss was $(16.1) million for the quarter.